NEWSWIRETODAY Press Release & Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Introduces New Click Chemistry Reagents - Click chemistry is a newer approach to the synthesis of drug-like molecules that can accelerate the drug discovery process
AnaSpec Introduces New Click Chemistry Reagents

 

NewswireTODAY - /newswire/ - Fremont, CA, United States, 2009/08/21 - Click chemistry is a newer approach to the synthesis of drug-like molecules that can accelerate the drug discovery process.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Click chemistry is a newer approach to the synthesis of drug-like molecules that can accelerate the drug discovery process. Sharpless, et al. defined what makes a click reaction as one that is wide in scope and easy to perform, uses only readily available reagents, and is insensitive to oxygen and water. Of the reactions comprising the click universe, the “perfect” example is the Huisgen 1,3-dipolar cycloaddition of alkynes to azides to form 1,4-disubstituted-1,2,3-triazoles (Scheme 1).1-4

Copper (I) species are powerful catalysts for the formation of 1,2,3-triazoles from azides and alkynes. The general thermodynamic instability of Cu(I) however, results in easy oxidation to Cu(II) and/or disproportionation to Cu(0) and Cu(II).1-4 TBTA, Tris-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine, also known as tris-(benzyltriazolylmethyl)amine, is a stabilizing ligand for Cu(I) developed by Tim Chan in Sharpless’ lab. TBTA protects Cu(I) from oxidation and disproportionation, while enhancing its catalytic activity.5 A C3-symmetric derivative, TBTS is an extremely useful ligand for azide-alkyne cycloaddition with ~106 fold of rate acceleration. Its tetradentate binding ability is able to completely envelop the Cu(I) center, leaving no free binding sites available for potential destabilizing interaction. Reactions are typically carried out with 1-2 mol % Cu(I) and TBTA without having to exclude oxygen and water.5

For use as a tool in the drug discovery process, AnaSpec is pleased to announce the availability of TBTA and a number of additional click chemistry reagents.
References:
1. Kolb, HC. And KB. Sharpless Drug Discovery Today 8, 1128 (2003).
2. Kolb, HC. et al. Angew. Chem. Int. Ed. 40, 2004 (2001).
3. Rostovtsev, VV. and KB. Sharpless Angew. Chem. Int. Ed. 41, 2596 (2002).
4. Tornøe, CW. et al. J. Org. Chem. 67, 3057 (2002).
5. Chan, TR. et al. Org. Lett. 6, 2853 (2004).

About AnaSpec
AnaSpec (anaspec.com) is a leading provider of integrated proteomics solutions to the world’s largest biotech, pharmaceutical, and academic research institutions. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and antibodies.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Introduces New Click Chemistry Reagents

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Ping Yang - AnaSpec.com 
510-791-9560 ping[.]anaspec.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen Completes Acquisition of ImCheck Therapeutics, Expanding Oncology Pipeline
NEC Presents Phase I Results for Personalized AI-Powered Oral Cancer Vaccine NECVAX-NEO1 at ESMO Immuno-Oncology Congress 2025
Ono Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera
JFCR, NEC, and Taiho to Develop Cancer Vaccines Utilizing Whole-Genome Information
Ono Receives Supplemental Approval of Combination Therapy with BRAFTOVI® Capsule, a BRAF Inhibitor, for the Indication of Colorectal Cancer
WuXi AppTec Receives Frost & Sullivan’s 2025 Global Company of the Year Recognition in the CRDMO Industry
Frost Radar™ Identifies Top Growth and Innovation Leaders in Pharmaceutical and Biotech Laboratory Information Management Systems
Ono Submits an Application for Approval of Cenobamate (ONO-2017), Antiseizure Medications in Japan
Viva Biotech Receives Frost & Sullivan’s 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry
Biotech Firm 4Dcell Selected to Showcase Next-Gen Cardiac Drug Testing Platform At EIC Corporate Day
Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
Ono and Bristol-Myers Squibb KK Receive Supplemental Approval of Opdivo and Yervoy in Combination Therapy in Japan
Ono Enters into A Definitive Agreement with Seikagaku for Co-development and Marketing Collaboration on Gel-One for the Treatment of Osteoarthritis
Deciphera Announces Positive CHMP Opinion for ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
Novotech Earns Frost & Sullivan’s 2025 Global Company of the Year Recognition for Excellence in Biotech Clinical Research Services

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2005-2025 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)